blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2972368

EP2972368 - LYMPHOCYTE BIOMARKERS FOR DETERMINING THE CLINICAL RESPONSE TO CELL THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.07.2020
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  21.06.2019
FormerGrant of patent is intended
Status updated on  12.02.2019
FormerExamination is in progress
Status updated on  13.01.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
TiGenix, S.A.U.
Parque Tecnológico de Madrid
C/ Marconi, 1
28760 Tres Cantos (Madrid) / ES
[2020/31]
Former [2019/30]For all designated states
TiGenix, S.A.U.
Parque Tecnológico de Madrid
C/ Marconi, 1
28760 Tres Cantos (Madrid) / ES
For all designated states
TIGENIX N.V.
Haarsrode Research Park 1724
Romeinse straat 12 bus 2
3001 Leuven / BE
Former [2016/03]For all designated states
TiGenix, S.A.U.
Parque Tecnológico de Madrid
C/ Marconi, 1
28760 Tres Cantos (Madrid) / ES
For all designated states
TIGENIX N.V.
Haarsrode Research Park 1724
Romeinse straat 12 bus 2
3001 Leuven / BE
Inventor(s)01 / DE LA ROSA, Olga
TiGenix S.A.U
Parque Tecnológico de Madrid
Marconi 1
E-28760 Tres Cantos - Madrid / ES
02 / LOMBARDO, Eleuterio
TiGenix S.A.U
Parque Tecnológico de Madrid
Marconi 1
E-28760 Tres Cantos - Madrid / ES
03 / DALEMANS, Wilfried
Tigenix NV
Romeinse straat 12 bus 2
B-3001 Leuven / BE
 [2016/03]
Representative(s)Lasar, Andrea Gisela
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2019/30]Lasar, Andrea Gisela
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2016/03]ABG Patentes, S.L.
Avenida de Burgos, 16D
Edificio Euromor
28036 Madrid / ES
Application number, filing date14712628.817.03.2014
[2016/03]
WO2014EP55282
Priority number, dateEP2013038209115.03.2013         Original published format: EP 13382091
[2016/03]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2014140362
Date:18.09.2014
Language:EN
[2014/38]
Type: A2 Application without search report 
No.:EP2972368
Date:20.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 18.09.2014 takes the place of the publication of the European patent application.
[2016/03]
Type: B1 Patent specification 
No.:EP2972368
Date:24.07.2019
Language:EN
[2019/30]
Search report(s)International search report - published on:EP16.04.2015
ClassificationIPC:G01N33/569
[2019/08]
CPC:
G01N33/56972 (EP,US); A61K35/35 (US); A61K35/28 (EP,US);
A61K35/33 (EP,US); A61K40/10 (EP,US); A61K40/22 (EP,US);
A61K40/416 (EP,US); A61P29/00 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/10 (EP); A61K2239/31 (EP,US); A61K2239/38 (EP,US);
A61K40/50 (EP,US); G01N2333/70514 (EP,US); G01N2333/70517 (EP,US);
G01N2333/70539 (EP,US); G01N2800/52 (EP,US) (-)
Former IPC [2016/03]G01N33/569, A61K35/14, A61P37/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/03]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:LYMPHOZYTEN-BIOMARKER ZUR BESTIMMUNG DES KLINISCHEN ANSPRECHENS AUF EINE ZELLTHERAPIE[2016/03]
English:LYMPHOCYTE BIOMARKERS FOR DETERMINING THE CLINICAL RESPONSE TO CELL THERAPY[2016/03]
French:BIOMARQUEURS LYMPHOCYTAIRES DESTINÉS À DÉTERMINER LA RÉPONSE CLINIQUE À UNE THÉRAPIE CELLULAIRE[2016/03]
Entry into regional phase15.10.2015National basic fee paid 
15.10.2015Designation fee(s) paid 
15.10.2015Examination fee paid 
Examination procedure15.10.2015Amendment by applicant (claims and/or description)
15.10.2015Examination requested  [2016/03]
31.08.2016Despatch of a communication from the examining division (Time limit: M04)
10.01.2017Reply to a communication from the examining division
02.05.2017Despatch of a communication from the examining division (Time limit: M04)
12.09.2017Reply to a communication from the examining division
05.12.2017Despatch of a communication from the examining division (Time limit: M04)
13.04.2018Reply to a communication from the examining division
17.07.2018Despatch of a communication from the examining division (Time limit: M04)
26.11.2018Reply to a communication from the examining division
13.02.2019Communication of intention to grant the patent
12.06.2019Fee for grant paid
12.06.2019Fee for publishing/printing paid
12.06.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19187915.4  / EP3581932
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  31.08.2016
Opposition(s)03.06.2020No opposition filed within time limit [2020/33]
Fees paidRenewal fee
01.03.2016Renewal fee patent year 03
06.03.2017Renewal fee patent year 04
06.03.2018Renewal fee patent year 05
08.03.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL24.07.2019
CY24.07.2019
EE24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
MC24.07.2019
MK24.07.2019
MT24.07.2019
RO24.07.2019
RS24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
IS24.11.2019
LU17.03.2020
[2022/32]
Former [2022/27]AL24.07.2019
CY24.07.2019
EE24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
MC24.07.2019
MT24.07.2019
RO24.07.2019
RS24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
IS24.11.2019
LU17.03.2020
Former [2021/04]AL24.07.2019
EE24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
MC24.07.2019
RO24.07.2019
RS24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
IS24.11.2019
LU17.03.2020
Former [2020/50]AL24.07.2019
EE24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
MC24.07.2019
RO24.07.2019
RS24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
IS24.11.2019
Former [2020/37]AL24.07.2019
EE24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
RO24.07.2019
RS24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
IS24.11.2019
Former [2020/36]AL24.07.2019
EE24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
RO24.07.2019
RS24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
IS24.11.2019
Former [2020/27]AL24.07.2019
EE24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
RO24.07.2019
RS24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
IS24.02.2020
Former [2020/24]AL24.07.2019
EE24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
RO24.07.2019
RS24.07.2019
BG24.10.2019
IS24.02.2020
Former [2020/23]AL24.07.2019
EE24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
RO24.07.2019
RS24.07.2019
BG24.10.2019
IS24.11.2019
Former [2020/22]AL24.07.2019
EE24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
RS24.07.2019
BG24.10.2019
IS24.11.2019
Former [2020/15]AL24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
RS24.07.2019
BG24.10.2019
IS24.11.2019
Former [2020/12]HR24.07.2019
LT24.07.2019
LV24.07.2019
RS24.07.2019
BG24.10.2019
IS24.11.2019
Former [2020/11]HR24.07.2019
LT24.07.2019
LV24.07.2019
RS24.07.2019
BG24.10.2019
Former [2020/10]LT24.07.2019
BG24.10.2019
Former [2020/08]LT24.07.2019
Cited inInternational search[Y]   OLGA DELAROSA ET AL: "Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases", CURRENT OPINION IN BIOTECHNOLOGY, vol. 23, no. 6, 1 December 2012 (2012-12-01), pages 978 - 983, XP055096416, ISSN: 0958-1669, DOI: 10.1016/j.copbio.2012.05.005 [Y] 1-6,8-14,16-18 * p. 979 Box 1 *

DOI:   http://dx.doi.org/10.1016/j.copbio.2012.05.005
 [A]   CLINICAL & INVESTIGATIVE SCIENCES GROUP (CLINICAL AND LABORATORY HAEMATOLOGY) ET AL: "Conditioning Protocols - allogeneic transplantation", 23 September 2012 (2012-09-23), XP055137189, Retrieved from the Internet [retrieved on 20140828] [A] 1-6,8-14,16-18 * the whole document *
 [Y]   KRAMPERA MAURO ET AL: "Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells", STEM CELLS, ALPHAMED PRESS, DAYTON, OH, US, vol. 24, no. 2, 1 February 2006 (2006-02-01), pages 386 - 398, XP002422937, ISSN: 1066-5099 [Y] 1-6,8-14,16-18 * p. 396 *
 [Y]   M KRAMPERA: "Mesenchymal stromal cell 'licensing': a multistep process", LEUKEMIA, vol. 25, no. 9, 1 September 2011 (2011-09-01), pages 1408 - 1414, XP055137780, ISSN: 0887-6924, DOI: 10.1038/leu.2011.108 [Y] 1-6,8-14,16-18 * p. 1911 *

DOI:   http://dx.doi.org/10.1038/leu.2011.108
 [IP]   DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 2013 (2013-10-01), WANG DANDAN ET AL: "A CD8 T Cell-IFN-gamma-IDO Axis Is Required For Mesenchymal Stem Cell Suppression Of Human SLE", XP002729197, Database accession no. PREV201300782514 [IP] 1-6,8-14,16-18 * abstract *
 [IP]   ARTHRITIS & RHEUMATISM, vol. 65, no. Suppl. 10, Sp. Iss. SI, October 2013 (2013-10-01), 77TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY / 48TH ANNUAL MEETING OF THE ASSOCIATION; SAN DIEGO, CA, USA; OCTOBER 25 -30, 2013, pages S674 - S675, ISSN: 0004-3591(print)
 [A]   DELAROSA OLGA ET AL: "Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells", TISSUE ENGINEERING, LARCHMONT, NY, US, vol. 15, no. 10, 7 October 2009 (2009-10-07), pages 2795 - 2806, XP002563369, ISSN: 1076-3279, [retrieved on 20090403], DOI: 10.1089/TEN.TEA.2008.0630 [A] 1-6,8-14,16-18 * the whole document *

DOI:   http://dx.doi.org/10.1089/ten.tea.2008.0630
Examination  YI LIU ET AL: "Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-[gamma] and TNF-[alpha]", NATURE MEDICINE, vol. 17, no. 12, 20 November 2011 (2011-11-20), pages 1594 - 1601, XP055178910, ISSN: 1078-8956, DOI: 10.1038/nm.2542

DOI:   http://dx.doi.org/10.1038/nm.2542
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.